Method for increasing bactericidal activity and providing virusocidal and fungicidal action on antibiotics |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Method for increasing bactericidal activity and providing virusocidal and fungicidal action on antibiotics (RU 2477124):
Method for enhancement of efficacy of e.coli resistant antibiotics / 2476210
Method under the invention involves detoxification and polymerisation of the tested antibiotics 150-200 mg/ml at first in 0.15±0.05% glutaric aldehyde at 38-40°C for 2-3 days, then in 0.1% aethonium or 0.1% alkyl dimethyl benzyl ammonium or 0.1% Biopague D at 38-40°C for 2-3 days.
 Method and plant to determine efficiency of adsorption immobilisation of microorganisms and monitoring of functional condition of biocatalysts based on immobilised microbial cells / 2475542
Thermostatting of a biocatalyst is carried out on the basis of immobilised microbial cells and a non-innoculated carrier within the biocatalyst, as well as infrared scanning of the biocatalyst surface and the carrier with the help of a highly sensitive infrared chamber, and production of thermal characteristics of the biocatalyst, such as distribution of temperatures on its surface and difference of temperatures between the surface of the biocatalyst and the non-innoculated carrier. Distribution of temperatures makes it possible to control homogeneity of activity distribution on the biocatalyst surface. The difference of temperatures is used to determine intensity of adsorption and metabolic activity of fixed bacterial cells. A plant for detection of efficiency of adsorption immobilisation of microorganisms and monitoring of functional condition of biocatalysts includes an infrared chamber fixed on a tripod, and connected with a computer, and a heat-insulating box with a hole on top, closed with a cover, which makes it possible to minimise oscillations of ambient temperature down to ±1°C/hr and reduces impact of the infrared chamber at analysis results.
 Method for differentiation of strains of vibrio cholerae serogroup 0139 by alkyl sulphate activity / 2473697
Invention refers to medical microbiology and concerns differentiation of toxigenic and non-toxigenic strains of cholera vibrios serogroup 0139. The described method involves preparing a synthetic medium 100 ml by using weights of: sodium chloride 0.5 g, agar 2 g, bromthymol blue 0.002 g; then the weight ingredients are dissolved in 0.01 M tris HCl buffer 100 ml, pH 7.8 and boiled for 30 minutes; the prepared medium is added with a substrate in the form of 1% aqueous sodium dodecyl sulphate (SDS) to the final concentration of 0.1% in the medium; it is followed by loop inoculation of the prepared medium on the analysed culture and incubation for 24-48 hours; the results are considered by the presence of milky-white areas 2-10 mm surrounding the inoculations on the agar sectors; the presence of those makes the strain to be referred to as toxicogenic (ctx+ tcp-), while the absence of those shows that the strain is non-toxicogenic (ctx+ tcp-).
Method of isolating uncultivable staphylococcus bacteria / 2470074
Invention relates to field of medicine, namely to microbiology and is intended for increasing efficiency of microbiological diagnostics of staphylococcal infections. Method of isolating uncultivable staphylococcus bacteria includes cultivation of studied material on beef-extract agar for 24 hours at temperature 37°C. After that, grown bacterial culture is kept at temperature +4°C for 48 hours.
 Culture medium for determining drug susceptibility of m tuberculosis to main anti-tuberculosis drugs / 2470071
Culture medium for determining drug susceptibility of Mycobacterium tuberculosis to four main drugs - streptomycin, isoniazid, rifampin and ethambutol contains: 4.7 g dry Middlebrook 7H9 broth, 1.25 g microbioligical agar-agar, 1.25 g pancreatic digest of casein, 900 ml distilled water and 100 ml growth additive OADC. The additive contains, g/l: sodium chloride 8.5, bovine albumin (fraction 5) 50.0, glucose 20.0, catalase 0.03 and oleic acid 0.6 ml/l.
Method of detecting antibodies to mycobacterium leprae on solid carrier / 2468371
Claimed is method of detecting antibodies to Mycobacterium leprae (M.leprae) on solid carrier. Places of application of components of immunologic reaction in ELISA on solid carrier (fluoroplastic tape) are sensitised with antigen from ultrasound disintegrate (sonicate) of M.leprae in dose 5 mcg/ml in volume 20 mcl for each sample of patients' blood serum. After that immunoperoxidase conjugate against human IgG is applied in the same volume on the places of previous location of reaction components. Unbound antigen from sensitised tape is removed with buffer solution (BPST) after each stage of reaction. Reaction results are estimated visually by difference in substrate mixture colouring.
Method of detecting viable probiotic microorganisms in in vitro conditions, imitating digestion process in humans / 2468087
In in vitro conditions, imitating digestion process in humans quantities of live microorganisms at the beginning and at the end of experiment are determined and their numeric values are compared. Conclusion is made on the basis of the results of comparison after incubation of probiotic microorganisms during 4 h in acidic model medium with acidin-pepsin by inoculation of microorganism suspension on dense nutritional medium. Grown colonies are counted and number of viable microorganisms is determined. Remaining suspension is separated from incubation medium, alkaline model medium with pansinorm forte 20000 is added to sediment in volume, analogous to volume of acidic model medium. Sediment is resuspended and suspension is incubatred during 12 hours, remaining number of viable microorganisms is determined by inoculation on a dense nutritional medium and counting grown colonies.
 Diagnostic technique for microsporia / 2458991
Diagnostic technique for microsporia in implemented by featuring clinical manifestations of the process, studying macro-and microphology of the culture. The presence of 1-2 centres of size 0.5-1.5 cm primarily localised on the scalp and the presence of two individual cell macroconidia in the form of a horseshoe with a thick pitted wall enable diagnosing microsporia caused Microsporum cams var.distortum. By using the complex of anamnestic, clinical, microscopic and morpho-biological signs, the invention allows establishing a precise etiological diagnosis of a microsporia agent - M canis var. distortum that is important in the process of the antimycotic therapy.
Method for recovering pure staphylococcus culture / 2458990
Method provides grinding a pathological biomaterial to be homogenated to prepare a suspensions. The prepared suspension is added with 3-5% citric acid at the basis of its content in the suspension. It is kept for 20-30 minutes at 10-20°C and added with 3-4% succinic acid and kept for 20-30 minutes at 10-20°C that is followed by neutrilising the suspension with 5-10% ammonium and reducing to pH 7.5-7.6. The neutrilised suspention is settled for 20-30 minutes; a supernatant is rinsed, and the precipitation is inoculated with a nutrient medium containing in 1 l of distilled water citric acid 8.0 g, ammonium citrate 2.0 g, succinic acid 3.0 g, asparagine or glycine 2.0 g, di-basic potassium phosphate 5.0 g, magnesium sulphate 0.5 g, zinc sulphate 0.3 g, di-basic sodium phosphate 3.0 g, sodium chloride 5.0-6.0 g, ferrous sulphate 0.1 g and glycerin 40-50 ml at pH 7.5-7.6. To produce the solid agar medium, the fluid medium diluted in distilled water 1:1 is added with agar 2.5 g per the fluid medium 100 ml, and sodium chloride is reduced to 5-6%.
 Diagnostic technique for clamidiosis, gardnerellosis, trichomoniasis, ureaplasmosis, mycoplasmosis by composition of equilibrium gas phase over cervical mucus / 2458139
Technique consists in total determination of the content of ammonium, amines and easily volatile carboxylic acids in an equilibrium gas phase over patient's cervical mucus with using an 'electronic nose' detector. The electronic nose has a package of 8 piezoelectric sensors and connected to a computer for data processing. Each sensor has a basic vibration frequency 10-15 MHz. The electrodes are coated with films of acetone solutions of bromocresol blue, methyl red, triton X-100, toluene solutions of polyethylene glycol 2000, polyethylene glycol adipinate, dicyclohexane-18-crown-6 and bee wax, and a chloroform suspension of multilayer carbon nanotubes. Total weight of each coating after solvent removal is 4-10 mcg. The technique is enabled by applying the equilibrium gas phase 1 cm over patient's cervical mucus in the cell of the device. The package of the piezoelectric sensors generate signals to be registered in the form of chronoperiodograms, the sorption parameters of ammonium, amines and easily volatile acids. The parameters are used to form a special data array and processed. The result is described as 'healthy' or 'sick' with specifying the disease: clamidiosis, candidiasis, gardnerellosis, trichomoniasis, ureaplasmosis, mycoplasmosis or their combination. The presence of pathogenic microorganisms in the cervical mucus sample is conditionally acceptable as +1, while the absence is coded as (-1) (reference values).
 Solid forms of macrolides / 2476438
Present invention refers to solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-micaminosyl-tylonolide having characteristics specified in the description. The application materials also present methods for preparing such crystalline forms. The invention declares a pharmaceutical composition for treating hemorrhagic septicemia, ruminant respiratory disease and swine respiratory disease, containing 20,23-dipiperidinyl-5-O-micaminosyl-tylonolide in the solid form wherein a therapeutically effective amount of 20,23-dipiperidinyl-5-O-micaminosyl-tylonolide in the composition consists of a substantially pure phase of the crystalline form or at least 50% of 20,23-dipiperidinyl-5-O-micaminosyl-tylonolide in the composition consists of a crystalline form.
 Formulation for disinfection and cleaning of removable blade dentures / 2476199
Invention refers to medicine, namely dental decontamination agents. A formulation for disinfection of removable dentures represents a solution of cetrimide, silver ions, a stabiliser, a perfume, chitosan succinate, water under certain proportions (wt %).
 Hybrid and tandem expression of neisserial proteins / 2475495
Invention relates to biotechnology, specifically obtaining immunogens from Neisseria meningitides and can be used in medicine. Disclosed is protein which is 80% or more identical to amino acid sequence SEQ ID NO:19, and an immunogenic composition with said protein.
 Method of treating endometritis in cows / 2475253
Invention relates to veterinary science. There are involved the intrauterine infusions of the ozonised emulsion 100.0 ml consisting of equal portions of cod liver oil and linseed infusion every 48 hours until clinical recovery is observed.
 Agent antiactinomycilline for treating actinomycosis and necrobacillosis in farm animals / 2475244
Invention relates to veterinary science. The agent contains, wt %: wildflower honey 3.0-5.0, pine turpentine 5.0-8.0, melted (cow) butter 12.0-15.0, anaesthesine 0.5-1.0, glycerol 0.5-1.5, ethanol 20.0-25.0, potassium iodide 2.0-2.5, salicylic acid 3.0-5.0, 9% vinegar 6.0-8.0, Novocaine (powder) 1.0-1.5, distilled water - the rest.
Method of treating acute and aggravated chronic laryngitis / 2474431
Invention refers to medicine and aims at treating acute and aggravated chronic laryngitis. What is involved is specific antibioticotherapy per os with additional examination of microflora starting from the 3rd-5th day of the therapy followed by instillations of specific, result-related bacteriophagues into the larynx in the amount of 0.5-1.0 ml in acute laryngitis for 7-10 days, and in aggravations for 10-14 days.
Universal vaccine for treating and preventing lyme disease applicable in human and veterinary science, and method for preparing it / 2472525
Invention refers to medicine, and concerns a universal vaccine for treating and preventing Lyme disease to be applied in veterinary science, based on a whole-cell bacterial vaccine or bacterial lysates or purified preparations, containing the three most pathogenic genospecies Borrelia burgdorferi sensu stricto, Borrelia afzelii and Borrelia garinii, each of which simultaneously contains both immunogenic protective proteins of the outer membranes OspA and OspC.
Moxifloxacin aqueous formulation for parenteral introduction / 2472507
Present invention refers to chemical-pharmaceutical industry and presents a moxifloxacin aqueous formulation for parenteral introduction containing an active substance: moxifloxacin hydrochloride, water for injections and other ingredients used for parenteral introduction differing by the fact that said ingredients are presented by sodium ascorbate and sodium metabisulphite in the following proportions, g/l: moxifloxacin hydrochloride 15-25; sodium ascorbate 0.05-1; sodium metabisulphite 0.1-2; water for injections up to 1 l.
 3-amino-6-(1-aminoethyl)tetrahydropyrane derivatives / 2471795
Invention refers to new antibacterial compounds of formula I
 Mutant antigens gas57 and gas57 antibodies / 2471497
Group of invention refers to medicine, particularly to producing a mutant antigen GAS57 containing an amino acid modification in two or more positions of amino acids specified in a group consisting of consisting of amino acids D151, H279 and S617 wherein said positions of amino acids are numbered according to SEQ ID N0:1 which is not able to split IL-8 and analogous substrates with keeping an ability to provide protection of the infections caused by S. pyogenes. The group of inventions also comprises a nucleic acid molecule coding a purified mutant antigen GAS57, a method for producing a mutant antigen, a composition and a method for producing it, a method for treating or preventing an infectious disease caused by S. pyogenes. Said mutants may be used inter alia in vaccine compositions.
 Capsule and drug preparation for preventing cardiovascular diseases / 2477123
Invention refers to pharmaceutical industry, particularly a drug preparation for preventing the development of cardiovascular diseases in individuals of a high-risk group. A capsule for preventing the development of cardiovascular diseases in individuals of a high-risk group which contains acetylsalicylic acid tablets coated by partially hydrolised polyvinyl alcohol (PVA), tablets of simvastatin and pravastatin coated by hydroxypropyl methylcellulose (HPMC) and tablets of lisinopril, ramipril or perindopril coated by partially hydrolised polyvinyl chloride. Using the capsule in producing the drug preparation for preventing the development of cardiovascular diseases in individuals of a high-risk group.
|
FIELD: medicine, pharmaceutics. SUBSTANCE: method under the invention provides detoxification and polymerisation of antibiotics in 0.15±0.05% glutaric aldehyde at 38-40°C for 3-5 days, and then in 0.1% alkyl dimethyl benzyl ammonium chloride at 38-40°C for 3-5 days. EFFECT: method provides effective bactericidal, virusocidal and fungicidal action of antibiotics and enables extending their therapeutic spectrum of application. 1 tbl, 4 ex
The invention relates to Microbiology and biotechnology. It is known that polymerization and detoxification of bacterial toxins and inactivation of viruses, bacteria are mainly formaldehyde, which is used from 1923 to obtain formulatin and anatoxins. At the same time, detoxification and polymerization of antibiotics on the principle of making anatoxins are not conducted. To increase the effectiveness of antibiotics injected into their structure pieperazinove radical, fluorine, clavulanic acid, creating a new generation of so-called "strong" antibiotics or combine with others. Combined use of some antibiotics with other leads to the emergence of drug-resistant microorganisms, while increasing nephro-, OTO-, neurotoxicity, etc. The creation of new dosage forms and combinations of antibiotics does not provide a significant breakthrough and reduce toxicity in pharmakinetic antimicrobial drugs. We first increased the bactericidal activity of antibiotics using 0,15±0,05% solution of formaldehyde on the principle of making anatoxina (iglewski A.A., Kolomiets V.M. way of increasing the effectiveness of antibiotics. Patent No. 2400218 priority from 06 April 2009). At the same time, the use of formaldehyde because of the carcinogenic properties, education in processorname highly toxic substances, precipitation at +9°C and below, contraindications for oral administration in many countries it is forbidden (Madunice NV Expert Committee on biological standardization who. Biologics, No. 1, 2001. - P.21-22). Currently studied that the glutaric aldehyde amino acids has greater antibacterial, antiviral and fungicidal action than the aldehyde and formic acid - formaldehyde. The prototype was taken way to increase the effectiveness of antibiotics by detoxification and polymerization 0,15±0,05% solution of formaldehyde (iglewski A.A., iglewski D.A. Modern aspects of increasing the effectiveness of antibiotics. Journal of the Kursk state agricultural Academy, No. 6. 2010 - P.64-65). The above-mentioned disadvantages of the use of formaldehyde and relatively inadequate bactericidal efficiency compared with glutaraldehyde and especially in combination with Quaternary ammonium compounds, including alkyldimethylbenzylammonium, identified the need for detoxification and polymerization of antibiotics for resistance to bacterial enzymes, but also provide increased antibacterial antiviral and antifungal actions. An object of the invention is to increase the effectiveness of antibiotics. The technical result is achieved by polymerization and detoxification of antibi the ticks first 0,15±0,05% solution of glutaraldehyde at 38-40°C for 3-5 days, and then 0.1% of alkyldimethylbenzylammonium in the same mode. The studies have used lincospectin, enrofloxacin, baytril, erythromycin, Amoksiklav, tetracycline, gentamicin, streptomycin, kanamycin, amoxicillin and Cefazolin, nystatin. Modified antibiotics detoxification and polymerization were studied for effectiveness against bacteria, fungi, and viruses. Application 0,15±0,05% solution of glutaraldehyde with 0.1% solution of alkyldimethylbenzylammonium (Quaternary ammonium compound) in the proposed method allows to check detoxification and polymerization of antibiotics on the principle of obtaining anatoxins and inactivated vaccines to increase their bactericidal activity and to provide antiviral and fungicidal action. In the patent and scientific and technical literature technical solutions are not found, similarly stated, using glutaraldehyde with alkyldimethylbenzylammonium that allows to make a conclusion about the compliance of the offer with the condition of patentability "novelty". The use of glutaraldehyde, alkyldimethylbenzylammonium and mode of detoxification and polymerization can achieve the effect specified in the invention, i.e. the claimed method meets the condition of patentability "inventive step". Proposed is the range of the method according to the principle of anatoxina creates the basis and the prospect of making new antibiotics, able to overcome the well-known defense mechanisms of microorganisms to expand therapeutic range of their application, therefore, declared the proposal meets the conditions of patentability "industrial applicability". The results obtained are illustrated by the following examples. Example 1. Synthesis of modified antibiotics was performed by dissolving 1.0 g of the drug in 8.0 ml of distilled water with the addition of 1.0 ml of 1% solution of glutaraldehyde for detoxification and curing at 38-40°C for 3-5 days, and then brought to 1.0 ml of 1% solution of alkyldimethylbenzylammonium for the second stage in the same mode. Modified detoxification and polymerization of lincospectin, enrofloxacin, baytril, erythromycin, Amoksiklav, tetracycline, gentamicin, streptomycin, kanamycin, amoxicillin, Cefazolin and nystatin retained transparency, did not change its color and properties within 2 years of storage at +5°C to 25°C. Example 2. Study of modified antibiotics toxicity Daily subcutaneous and intramuscular injection of modified antibiotics for 5-7 days white mice in 0.1 ml (10 mg), cavies 2.0 ml (200 mg), piglets weighing 3-4 kg 10 ml (1 g) and calves weighing 40-50 kg 15-20 ml (1.5-2.0 g) did not cause necrotic changes in the injection of drugs and clincheck is marked toxic symptoms in the absence of death. Example 3. Study of toxicity of modified antibiotics for oral use with water and food by watering and feeding within 7-10 days 1-2 ml (100-200 mg) chickens-broilers (50 goals), 27 calves 30-50 ml (3,0-5,0 g) and 35 pigs 10-20 ml (1-2 g) did not cause toxic signs and death. Example 4. The study of the spectrum of the modified polymerization and detoxification of antibiotics using glutaraldehyde with alkyldimethylbenzylammonium held against staphylococci, E.coli, Salmonella, Pseudomonas aeruginosa, poxviruses of fibromatosis and myxomatosis virus canine distemper, parvovirus dogs, polykemi cats and mushrooms - Asp. niger Candida albicanis and Asp. flavus. The results are presented in table 1. Spectrum bactericidal and fungicidal action of modified antibiotics for 100 thousand of microorganisms in 1 ml 1 ág/ml, where To control, commercial antibiotic, and M is modified. From the data presented in table 1, it follows that the bactericidal effectiveness of antibiotics, modified detoxification and polymerization 0,15±0,05% solution of alkyldimethylbenzylammonium, virtually increased more than twice compared to commercial preparations against staphylococci, Escherichia, and Pseudomonas aeruginosa and Salmonella, which provided antifungal dei is a journey for Aspergillus niger, flavus and albikans with average minimum overwhelming concentration of 40-90 mg/ml, which correlate with therapeutic doses. Subsequently it was established antiviral effect of modified antibiotics in concentrations of 10-20 µg/ml against poxviruses of fibromatosis and myxomatosis virus, plague and enteritis in dogs and polykemi cats with 103-105infectious doses in 1 ml.
The way to increase bactericidal activity and provide antiviral and antifungal effect of antibiotics, namely, that carry out detoxification and polymerization of antibiotics first 0,15±0,05%solution of glutaraldehyde at 38-40°C for 3-5 days, and the ATEM 0,1%solution alkyldimethyl ammonium at 38-40°C for 3-5 days.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||